Biotechnology
GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies
SHANGHAI, Dec. 31, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of$75 million (~500 million RMB) series C financing. This round of financing is led by Huagai ...
2021-12-31 19:00
1908
China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally
HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...
2021-12-30 20:00
2195
Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology
SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...
2021-12-30 19:18
2229
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
SHANGHAI and HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...
2021-12-30 09:51
3117
Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane
* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...
2021-12-29 19:00
3538
Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China
GUANGZHOU, China, Dec. 29, 2021 /PRNewswire/ -- The inauguration ceremony of
Biosyngen Pte. Ltd., ("Biosyngen") joint projects and Biosyngen biological
production base was held inChina-Singapore Guangzhou Knowledge City (CSGKC), on
December 28th , 2021.
2021-12-29 10:00
4374
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
GAITHERSBURG, Md. and PUNE, India, Dec. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine m...
2021-12-29 03:57
2995
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...
2021-12-28 22:00
1627
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...
2021-12-28 09:00
1307
Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase
SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the "Emerging Company Showcase" that was held earlier this month inNew York. Dr. Guy Rosenthal, Vice President, Head of C...
2021-12-24 16:30
3522
Convidecia™ Phase III Results Published in The Lancet
* 96.0% effective against severe disease 14 days post-vaccination for population aged 18 and above. * Single-dose vaccine received approvals in at least 10 markets including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia. TIANJIN, China, Dec. ...
2021-12-24 15:28
6087
Novavax and SK bioscience Expand Manufacturing Agreement
- Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market GAITHERSBURG, Md., Dec. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializin...
2021-12-24 07:30
2758
Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice
STOCKHOLM, Dec. 23, 2021 /PRNewswire/ -- Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founderHelena Edlund of a new study demonstrating the prevention and reversal of gene expression and epigenetic changes to beta c...
2021-12-23 22:05
2578
Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'
DAEJEON, South Korea, Dec. 23, 2021 Curocell, currently on PhaseⅠCAR-T Therapy
clinical trial withCRC01 (anbalcabtagene autoleucel) has recently broken ground
for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon
International Science & Business Belt.
2021-12-23 20:00
1988
Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets
CHONGQING, China, Dec. 23, 2021 /PRNewswire/ -- Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19th National Psychiatry Conference of the Chinese Medica...
2021-12-23 16:23
2376
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surf...
2021-12-23 09:00
2537
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
SHANGHAI, Dec. 22, 2021 /PRNewswire/ -- Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma ("Nuance"), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive a...
2021-12-23 07:44
1634
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise...
2021-12-23 05:54
2821
Origin Agritech Developing Nutrition Enhanced Corn Using CRISPR Gene Editing
BEIJING, Dec. 22, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that it is developing nutritionally enhanced corn using CRISPR technology. Origin is currently in trials to develop new corn varieties that ha...
2021-12-23 01:15
2128
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy
- Additional research centers now enrolling patients in Australia and New Zealand - Company has achieved 50 percent of target enrollment in global Phase 3 trial LONDON, Dec. 23, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on r...
2021-12-22 21:00
1697
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 320 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 298 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 287 media titles]
2024-04-12 15:14
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 274 media titles]
2024-04-15 08:00
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 273 media titles]
2024-04-11 11:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
6274
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
5310
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
4406
Cognizant Teams with Shopify and Google Cloud To Transform Enterprise Retail
2024-04-09 12:01
3534
PENSKE AUTOMOTIVE GROUP TO EXPAND RETAIL AUTOMOTIVE PRESENCE INTO AUSTRALIA
2024-04-09 04:15
3292